Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Metformin, the widely used drug in the treatment of TIIDM, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 11/June/2017, 12.10 am

Natural product-derived therapy for prostate cancer bone metastasis: Myrtenol, found in Cardamom, inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via up regulation of its target gene, 11/June/2017, 12.05 am
June 10, 2017
Amino-acid based PD-1 pathway activation for Pain therapy: Taurine, isolated from Soy products, increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 11/June/2017, 12.17 am
June 10, 2017
Show all

Introduction:What they say:

A recent study from Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA shows that “Deubiquitination and Stabilization of PD-L1 by CSN5.” This study was published in the 12 December 2016 issue of Cancer cell (one of the best journals in Cancer Science with an impact factor of 23.523) by Prof Mien-Chie Hung, Lim SO and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Metformin, the widely used drug in the treatment of TIIDM, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene


What is known?

It has recently been shown that blocking cell surface receptor PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year recently.


From Research Findings to Therapeutic opportunity

Metformin, by increasing the expression of its target gene, it may  ubiquitinate and destabilize PD-L1 (fig. 1). Thereby, it may: (i) diminish PD-L1 expression in cancer cells; (ii) inhibit inflammatory TNFα signaling; (iii) decrease the number of tumor-infiltrating lymphocytes and macrophages; (iv) increase T-cell anti-tumor immunity; (v) decrease tumor burden; and (vi) increase survival of patients with breast cancer (fig. 1).  

Figure 1. Mechanistic insight into how Metformin enhances the efficacy of cancer immunotherapy. Metformin, by decreasing the expression of PD-L1 in cancer cells, it augments T-cell mediated anti-tumor immunity

Thus, pharmacological formulations encompassing “Metformin or its analogues, either alone or in combination with other drugs may be used to (i) inhibit the progression of tumors; and (ii) enhance the efficacy of Cancer immunotherapy.price-50

[easy_payment currency=”USD”]


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $50

Undisclosed mechanistic information: How Metformin suppresses the expression of PD-L1 and augments anti-tumor immunity

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References

Citation: Boominathan, L., Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Metformin, the widely used drug in the treatment of TIIDM, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 11/June/2017, 12.10 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.